| Bioactivity | Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models[1][2]. | ||||||||||||
| In Vivo | Centhaquine (Centhaquin) (intravenous injection, 0.01-1.0 mg/kg; intraduodenal administration 1.0-2.5 mg/kg) lowers the blood pressure and reduced the heart rate of anaesthetized and unanaesthetized (decerebrate) cat in a dose-dependent manner[1].Centhaquine (Centhaquin) (intravertebral arterial injection; 5-10 μg) or by topical application to the exposed ventral surface of medulla or floor of the fourth ventricle causes hypotension and bradycardia as well as reduced the excitability of the vasomotor loci[1].Centhaquine (Centhaquin;PMZ-2010) (intravenous administration; 0.015mg/kg) can attenuate the deleterious effects of catecholamines, improving both the macro- and microcirculation during CPR[2]. Animal Model: | ||||||||||||
| Name | Centhaquin | ||||||||||||
| CAS | 57961-90-7 | ||||||||||||
| Formula | C22H25N3 | ||||||||||||
| Molar Mass | 331.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Srimal RC,et al. Pharmacological studies on 2-(2-(4-(3-methylphenyl)-1-piperazinyl)ethyl) quinoline (centhaquin). I. Hypotensive activity.Pharmacol Res. 1990 May-Jun;22(3):319-29. [2]. Papalexopoulou K, et al. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest.Heart Lung Circ. 2017 Aug;26(8):856-863. |